US/UK/Canada

Share

Quotes

This project with Amicogen is incredibly interesting and creates very good conditions for a deeper collaboration in the future. With this agrement, Amicogen and Bio-Works will establish the first local production of agarose-based resins in South Korea
says Jonathan Royce, CEO at Bio-Works Technologies.
Pick a time period -
Tags ( Active)

Resolutions passed at Bio-Works Technologies’ annual general meeting 2026

Bio-Works Technologies’ annual general meeting was held on 4 June 2026. The following resolutions were passed at the annual general meeting, among other resolutions. The meeting adopted the income statement and balance sheet and the consolidated income statement and consolidated balance sheet for the financial year 2025. The meeting resolved that no dividend shall be paid for the financial year 2025. The meeting granted the board members and CEO discharge from liability for the financial year 2025. The meeting resolved that the number of board members shall be six and re-elected

Bio-Works reports first quarter 2026

Summary of the quarter January – March 2026 (January – March 2025) · Net sales for the first quarter amounted to 29.3 (9.0) MSEK, an increase of 20.3 MSEK. Sales growth has been strong during the quarter, particularly driven by large deliveries in Europe. · Operating profit for the quarter amounted to 4.1 (-7.8) MSEK. · Profit for the quarter was 4.7 (-8.0) MSEK. · Cash flow for the period amounted to +6.3 (-4.4) MSEK · Order intake for the first quarter totaled 15.5 (31.6) MSEK, a decrease of 16.1 MSEK (order value converted at the exchange rate at the time of order).

Bio-Works receives order for WorkBeads 40S from contract manufacturer in Europe

Bio-Works Technologies AB has received an order for 230 liters of WorkBeads 40S, valued at approximately 4,2 million SEK, from a returning European customer active in contract manufacturing of peptides. “The order confirms the continued confidence in Bio-Works as a supplier of high-quality chromatography products and highlights the strong position of WorkBeads 40S in the growing peptide purification market,” says Lone Carlbom, CEO of Bio-Works Technologies AB. Delivery is planned for Q3 2026, and the order contributes positively to Bio-Works’ sales targets for the year. Contacts:

Bio-Works Technologies AB announces outcome from exercise of warrants of series TO 2. Exercise period 6 of 11

THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, JAPAN, CANADA, NEW ZEALAND, SOUTH AFRICA, HONG KONG, SWITZERLAND, SINGAPORE, THE UNITED KINGDOM, SOUTH KOREA, RUSSIA, BELARUS OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE UNLAWFUL OR DEMAND ADDITIONAL REGISTRATION OR OTHER MEASURES BEYOND WHAT IS REQUIRED UNDER SWEDISH LAW. PLEASE SEE “IMPORTANT INFORMATION” AT THE END OF THIS PRESS RELEASE.On 16 April 2026, the sixth exercise period for Bio-Works Technologies AB's (“

Proposed New Board Members in Bio-Works

In its motivated opinion to the 2026 Annual General Meeting of Bio-Works Technologies AB, the Nomination Committee proposes the election of two new board members: Eva Lindskog and Andrea Ballagi. In addition, the committee proposes the re-election of Peter Ehrenheim, Peter Nählstedt, Jonas Ahlén, and Thomas Gür. Ehrenheim is also proposed for re-election as Chairman of the Board.Eva Lindskog, born in 1973, has more than 15 years of experience in senior positions within the Life Science industry, with a focus on bioprocessing, contract manufacturing, and analytical technologies. She

Bio-Works Technologies AB - Business Update first quarter 2026

Net Sales:                                    MSEK       Compare                                                       First quarter 2026                           29,3             (9,0)         Last two quarters                            53,0           (11,6)                                            Last four quarters                           82,8            (28,5)    Order intake:                                MSEK       Compare First quarter 2026                           15,5            (31,6)       Order-book on 2026-03-31           17,7        The sales and

Today is the first day of the sixth exercise period for Bio-Works Technologies AB's warrants of series TO 2

THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, JAPAN, CANADA, NEW ZEALAND, SOUTH AFRICA, HONG KONG, SWITZERLAND, SINGAPORE, SOUTH KOREA, RUSSIA, BELARUS OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE UNLAWFUL OR DEMAND ADDITIONAL REGISTRATION OR OTHER MEASURES BEYOND WHAT IS REQUIRED UNDER SWEDISH LAW.Today, 1 April 2026, is the first day of the sixth exercise period for Bio-Works Technologies AB (“Bio-Works” or the “Company”) warrants of series TO 2 (“TO 2”),

Bio-Works Technologies AB publishes Business Update ahead of next value creation phase

Bio-Works Technologies AB (“Bio-Works” or the “Company”) hereby publishes an operational and financial update in connection with a meeting with investors conducted by the Company’s management and Board of Directors on Friday, March 6. The information is such that Bio-Works is obliged to disclose pursuant to the EU Market Abuse Regulation (MAR). The Company reports continued progress in line with its previously communicated strategy, with improved financial performance, strengthened commercial activity, and a fully funded plan through to break-even.Commercial Development A key

Bio-Works publishes Year-end report Q4 2025

Fourth quarter in review Oct – Dec 2025 (Oct - Dec 2024) · Net sales in the fourth quarter were 23.7 (2.6) MSEK, an increase of 21.1 MSEK. · Operating profit in the quarter amounted to  -0.9 (-13.8) MSEK. The improvement is explained by the strong sales increase in the quarter.  · Profit for the fourth quarter was 1.4 (-13.2) MSEK. The ruling in the Supreme Administrative Court in favor of Bio-Works against the Swedish Tax agency had a positive impact of +2.0 MSEK. The tax surcharge was recognized as an expense in 2023 annual report, due to the uncertainty of appeal.   ·

Bio-Works Receives Order from Returning Customer

Bio-Works Technologies AB has received a new order from a returning customer with an order value of 11 MSEK. The order relates to the delivery of the company’s chromatography products and further strengthens the ongoing collaboration between the parties.The customer operates within the biopharmaceutical industry and has previously used Bio-Works’ products in its process development and production activities. “We are pleased with the continued trust from our customer. Repeat orders confirm that our products deliver value and quality in our customers’ processes,” says Lone Carlbom, CEO of

Bio-Works Technologies AB announces outcome from exercise of warrants of series TO 2. Exercise period 5 of 11

THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, JAPAN, CANADA, NEW ZEALAND, SOUTH AFRICA, HONG KONG, SWITZERLAND, SINGAPORE, THE UNITED KINGDOM, SOUTH KOREA, RUSSIA, BELARUS OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE UNLAWFUL OR DEMAND ADDITIONAL REGISTRATION OR OTHER MEASURES BEYOND WHAT IS REQUIRED UNDER SWEDISH LAW. PLEASE SEE “IMPORTANT INFORMATION” AT THE END OF THIS PRESS RELEASE.On 16 January 2026, the fifth exercise period for Bio-Works Technologies AB's

Today is the first day of the fifth exercise period for Bio-Works Technologies AB's warrants of series TO 2

THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, JAPAN, CANADA, NEW ZEALAND, SOUTH AFRICA, HONG KONG, SWITZERLAND, SINGAPORE, SOUTH KOREA, RUSSIA, BELARUS OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE UNLAWFUL OR DEMAND ADDITIONAL REGISTRATION OR OTHER MEASURES BEYOND WHAT IS REQUIRED UNDER SWEDISH LAW. Today, 2 January 2026, is the first day of the fifth exercise period for Bio-Works Technologies AB (“Bio-Works” or the “Company”) warrants of series TO 2 (“TO 2”),

Business Update

The Board of Directors in Bio-Works Technologies AB has made the decision to send out a business update on a quarterly basis, beginning with the fourth quarter 2025. We will be reporting net sales, the orderbook and the order intake for the last quarter directly after the closing of the quarter. The business update will give owners and investors information more quickly and give a better understanding of the company’s development. Bio-Works Technologies Business Update fourth quarter 2025 Net Sales:                                MSEK        Compare

Bio-Works Receives Two WorkBeads 100S and 100Q Orders Worth SEK 4 Million

Bio-Works Technologies AB has received two orders from a recurring customer in India for WorkBeads 100S and WorkBeads 100Q. The total order value amounts to approximately SEK 4 million.The deliveries are scheduled for Q1–Q2 2026 and strengthen the company’s order book for the coming year. The orders confirm the growing demand for Bio-Works’ scalable and cost-efficient affinity solutions for biopharmaceutical manufacturing. “This transaction demonstrates both the strength of our long-term customer relationships and the increasing global demand for our WorkBeads products. It supports

Bio-Works Technologies AB Annual General Meeting to be held on Thursday 4 of June 2026

The Annual General Meeting of Bio-Works Technologies AB will be held on Thursday, June 4, 2026, at the company's head office in Uppsala, Sweden. ContactsFor more information, please visit the Bio-Works homepage at, www.bio-works.com or contact: Arne Hauge, CFO, e-mail: arne.hauge@bio-works.com, phone: +46(0)8-502 705 83. About Bio-WorksBio-Works enables Biotech companies to achieve their goals for purification of biomolecules. We support our customers, from laboratory research to commercial production, and together we implement efficient and robust solutions for bioprocessing. Our

Bio-Works reports third quarter 2025

The third quarter in reviewThird quarter (July – September 2025) · Net sales in the third quarter were 16,6 (9,8) MSEK, an increase of 70%. · Operating profit in the quarter amounted to -1,2 (-5,1) MSEK. The improvement can be explained by the sales increase during the quarter, and personnel costs and operating expenditures following plan.  · Profit for the quarter was -1,4 (-5,3) MSEK. · Cash flow from operating activities was –7,1 (-6,6) MSEK. · The order intake for the third quarter was 10,0 (3,1) MSEK, an increase of 6,9 MSEK. · Personnel costs and other external

Bio-Works receives order for WorkBeads 40S from contract manufacturer in Europe

Bio-Works Technologies AB has received an order for 190 liters of WorkBeads 40S, valued at approximately 4 million SEK, from a returning European customer active in contract manufacturing of peptides.“The order confirms the continued confidence in Bio-Works as a supplier of high-quality chromatography products and highlights the strong position of WorkBeads 40S in the growing peptide purification market,” says Lone Carlbom, CEO of Bio-Works Technologies AB. Delivery is planned for Q1 2026, and the order contributes positively to Bio-Works’ sales targets for the year.

Bio-Works forms strategic partnership with Zenmindes Biotechnology to strengthen presence in China

Bio-Works Technologies AB today announced a strategic partnership with Zenmindes Biotechnology Co., Ltd., aimed at establishing a strong and sustainable presence in China’s rapidly expanding biopharmaceutical market.China is one of the world’s most dynamic biopharma markets, marked by a growing demand for high-performance chromatography resins. Through this collaboration, Bio-Works takes a significant step forward in meeting that demand with local expertise, dedicated support, and a long-term growth strategy. “This partnership marks an important milestone in our global expansion journey.

Bio-Works two largest shareholders, members of the board and the CEO have all exercised all their Warrants TO2

Bio-Works two largest shareholders, Staffan Persson and Erik Åfors, the chairman of the board Peter Ehrenheim, and members of the board Thomas Gür and Jonas Ahlén and the CEO, have all exercised their TO2 Warrants in accordance with intention expressed in press releases of the 18 and 19 of August. Bio-Works Technologies AB’s announced, on the 16’th of October, that a total of 17,854,180 TO 2 Warrants were exercised during the fourth exercise period.  Bio-Works thus received SEK 17,854,180 before issue costs. All four board members in Bio-Works have now exercised all their Warrants TO2.

Correction: Bio-Works receives order for WorkBeads™ affimAb valued at approximately SEK 8.3 million

This press release was wrongfully not tagged as information that Bio-Works Technologies AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). Bio-Works Technologies AB today announces that the company has received an order from a returning customer in Europe for 69 liters of WorkBeads™ affimAb, valued at approximately SEK 8.3 million. Deliveries are scheduled for the first and second quarters of 2026.The order confirms continued trust from the customer and underscores Bio-Works’ strong position as a supplier of high-quality chromatography products to

Bio-Works receives order for WorkBeads™ affimAb valued at approximately SEK 8.3 million

Bio-Works Technologies AB today announces that the company has received an order from a returning customer in Europe for 69 liters of WorkBeads™ affimAb, valued at approximately SEK 8.3 million. Deliveries are scheduled for the first and second quarters of 2026.The order confirms continued trust from the customer and underscores Bio-Works’ strong position as a supplier of high-quality chromatography products to the biotechnology and biopharmaceutical industries. “Receiving this repeat order from an established customer is clear proof that our products deliver on quality and performance.

Bio-Works Technologies AB announces outcome from exercise of warrants of series TO 2. Exercise period 4 of 11

THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, JAPAN, CANADA, NEW ZEALAND, SOUTH AFRICA, HONG KONG, SWITZERLAND, SINGAPORE, THE UNITED KINGDOM, SOUTH KOREA, RUSSIA, BELARUS OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE UNLAWFUL OR DEMAND ADDITIONAL REGISTRATION OR OTHER MEASURES BEYOND WHAT IS REQUIRED UNDER SWEDISH LAW. PLEASE SEE “IMPORTANT INFORMATION” AT THE END OF THIS PRESS RELEASE.On 14 October 2025, the fourth exercise period for Bio-Works Technologies AB'

Strong interest in WorkBeads™ affimAb Edge: Next-Generation Protein A Resin for Antibody Purification

Bio-Works Technologies AB announced on August 19th, 2025, the launch of  WorkBeads™ affimAb Edge, a resin with market leading performance designed for efficient purification of monoclonal antibodies and Fc-containing fragments or fusion proteins from laboratory to production scale.Built on an improved macroporous agarose-based matrix and coupled with an alkali-stable recombinant Protein A ligand, WorkBeads affimAb Edge delivers: · High performance and process economy: Dynamic binding capacities exceeding 70 mg/mL at 6 minutes residence time. · Superior pressure flow properties:

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe